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Polymorphisms of the vitamin D receptor gene (VDR) have been shown to be associated with several complex
diseases, including osteoporosis, but the mechanisms are unknown and study results have been inconsistent. We
therefore determined sequence variation across the major relevant parts of VDR, including construction of linkage
disequilibrium blocks and identiﬁcation of haplotype alleles. We analyzed 15 haplotype-tagging SNPs in relation
to 937 clinical fractures recorded in 6,148 elderly whites over a follow-up period of 7.4 years. Haplotype alleles
of the 5′ 1a/1e, 1b promoter region and of the 3′ untranslated region (UTR) were strongly associated with increased
fracture risk. For the 16% of subjects who had risk genotypes at both regions, their risk increased 48% for clinical
fractures (Pp .0002), independent of age, sex, height, weight, and bonemineral density. The population-attributable
risk varied between 1% and 12% for each block and was 4% for the combined VDR risk genotypes. Functional
analysis of the variants demonstrated 53% lower expression of a reporter construct with the 1e/1a promoter risk
haplotype (P p 5 # 1057) in two cell lines and 15% lower mRNA level of VDR expression constructs carrying
3′-UTR risk haplotype 1 in ﬁve cell lines (Pp 2 # 1056). In a further analysis, we showed 30% increased mRNA
decay in an osteoblast cell line for the construct carrying the 3′-UTR risk haplotype (Pp .02). This comprehensive
candidate-gene analysis demonstrates that the risk allele of multiple VDR polymorphisms results in lower VDR
mRNA levels. This could impact the vitamin D signaling efﬁciency and might contribute to the increased fracture
risk we observed for these risk haplotype alleles.
Introduction
The vitamin D receptor (VDR [MIM 601769]) (12q13)
is a steroid receptor acting as a transcription factor re-
sponding to the biologically active form of the seco-
steroid vitamin D hormone. The vitamin D endocrine
system is pleiotropic and plays an important role in skel-
etal metabolism, including intestinal calcium absorption
and regulation of osteoblast differentiation, but it has
also been shown to modulate immune response, insulin
secretion, the renin/angiotension system, and growth of
cancer cells (Haussler et al. 1998).
Rare, deleterious mutations in the VDR gene cause
the well-known 1,25-dihydroxyvitamin D–resistant
rickets (rickets type II), a rare monogenetic disease char-
acterized by osteomalacia, alopecia, and increased 1,25-
(OH)2D3 levels. Some isolated, more common VDR
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SNPs have previously been associated with several com-
plex diseases and traits, such as osteoporosis (Morrison
et al. 1994; Young et al. 1996; Uitterlinden et al. 2001;
Fang et al. 2003). However, the relationship between
disease and haplotype alleles across VDR has not been
systematically analyzed, and their effects on VDR func-
tion are poorly understood.
The interpretation of polymorphic variations in VDR
is severely hindered by the fact that, until now, only a
few polymorphisms in this large gene have been studied
and that most of these are anonymous (nonfunctional)
polymorphisms. To explain the associations observed
with complex diseases, they should be in linkage dis-
equilibrium (LD) with truly functional polymorphisms.
Haplotype-based methods offer a powerful approach to
studying the association of genetic variation with com-
plex disease (Gabriel et al. 2002). Following a recent
study of VDR polymorphisms (Nejentsev et al. 2004),
we here present a detailed description of the genomic
organization of the VDR gene region, the identiﬁcation
of 62 polymorphisms across relevant areas of the gene,
and an analysis of LD and haplotype diversity of VDR
variations in different ethnic groups. We use this infor-
mation in a large-scale association analysis of haplo-
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Figure 1 Genomic structure and LD map of the human VDR gene. a, Physical organization of the 12q12 area containing VDR, mostly
based on the Celera database (kb 47032–47145 at chromosome 12q12). The arrows for each gene indicate the transcription direction, and
distances are in kb. b, Genomic structure of the human VDR gene. Black bars indicate the coding exons of VDR, and the gray bars indicate
5′ exons and the 3′ UTR. c, Sequenced areas and positions of the 62 variations. Gray bars in the 3′-UTR indicate destabilizing elements (DE
1, 2, and 3 [Durrin et al. 1999]). The sequence-variation numbers refer to those given in table 3. d, Haplotype map of VDR in whites, Asians,
and African Americans, based on SNPs with an MAF 5% in each of the different ethnic populations. Common haplotype alleles in each block
with a frequency 13% are presented below the blocks. SNPs and alleles in red indicate htSNPs. Fracture-risk haplotype alleles are underlined.
The correspondence is shown for whites to haplotypes in block 5 of the BsmI-ApaI-TaqI haplotype alleles we deﬁned elsewhere (Uitterlinden
et al. 1996).
Table 1
Allele Frequencies of 47 SNPs in Different Ethnic Groups
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
type-tagging SNPs (htSNPs) in relation to osteoporosis
in a group of 6,148 white elderly men and women. We
analyzed functionality of relevant polymorphisms in the
promoter and 3′ UTR to help understand the underlying
mechanism of the association we observed.
Material and Methods
Subjects
We sequenced genomic DNA (see supplementary ma-
terial and methods in online-only appendix A) from 15
young white individuals, including ﬁve homozygotes for
each major VDR 3′-UTR haplotype—that is, 11, 22, and
33, as deﬁned in a previous study (Uitterlinden et al.
1996) on the basis of BsmI, ApaI, and TaqI RFLPs. We
studied LD in 234 randomwhite blood-bank donor sam-
ples and in DNA from 107 Asian and 58 African in-
dividuals (from the Coriell Institute: 90 Chinese Han
[group HD100], 9 Chinese [HD02], 8 Japanese [HD07],
47 African Americans [HD04 and HD50], and 9 Afri-
cans from south of the Sahara [HD12]). The associa-
tion of VDR genotype with fracture risk was analyzed
in the Rotterdam Study with 7,983 subjects (Hofman
et al. 1991); DNA was collected from 6,580 of them,
and 6,148 DNA samples were available for which geno-
typing of all SNPs was successful. Genomic DNA
was isolated from blood in accordance with standard
procedures.
Genotyping
We genotyped 47 SNPs (table 1) in three ethnic groups
and 14 htSNPs and FokI, BsmI, ApaI, and TaqI RFLPs
in 6,148 white subjects from the Rotterdam Study, with
the use of high-throughput TaqMan allelic discrimina-
tion assays. The assay mixes (including unlabeled PCR
primers, FAM and VIC dye-labeled TaqMan MGB
probes) of three Assays-on-Demand and 36 Assays-by-
Design were designed and provided by Applied Biosys-
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Table 2
Oligonucleotides for EMSA
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 3
Sequence Variations of VDR Determined
by Sequence Analysis of 30 White Chromosomes
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
tems (ABI). The reaction system contained 1–5 ng of
dried genomic DNA, 2.5 ml of TaqMan Universal PCR
Master Mix, 2 # No AmpErase UNG, 0.125 ml 40 #
Assay Mix or 0.0625 ml 80# Assay Mix and was ad-
justed with Milli-Q H2O for a total volume of 5 ml. The
genotyping results were analyzed using independent
end-point readings by two operators of the ABI Prism
7900HT, and a random 5% of samples were indepen-
dently repeated to conﬁrm genotyping results. The dis-
agreement rate varied from 0.3% to 1.2% for ﬁve
htSNPs, whereas the genotype results for all other
htSNPs were completely consistent.
Sequence Analysis, LD, and Haplotype Analyses
Human and mouse VDR genomic sequences (1105 kb
from the Celera database) were analyzed using the Vista
program (Vista Tools Web site) to visualize the pairwise
percentage identity as calculated for every 100 bp. We
used the TFSEARCH program (TFSEARCH: Searching
Transcription Factor Binding Sites Web site) from the
TRANSFAC databases developed by GBF-Braunschweig
and the MetInspector from Genomatix software GmbH
to search for potential transcription-factor binding sites
(TFBSs) around promoter polymorphisms.
We ﬁrst analyzed LD among all 62 polymorphisms
determined on the basis of 15 sequenced white samples,
to select 37 SNPs; we also included an additional 9 SNPs
(A to I in ﬁg. 1A and table 1) that ﬂank VDR from the
Celera database and E8-G284A (a BsmI RFLP) (Mor-
rison et al. 1992). (For polymorphism nomenclature, the
ﬁrst element of the polymorphism ID is the designation
of exon [coding exons begin with capital “E”] or 3′-
UTR [“U”]; in most IDs, this is followed by a hyphen
and the major nucleotide allele [for whites]; then, the
nucleotide location is designated as plus [] or minus
[], relative to the ﬁrst or last base of the nearest exon,
or is shown without a sign if it is in the exon; and the
last element of the polymorphism ID is the minor nu-
cleotide allele [for whites].) Selection criteria for VDR
SNPs in the LD analysis is based on whether the SNP
(1) has a minor-allele frequency (MAF) 110% (3/30 al-
leles), as determined by our sequence analysis; (2) is in
a potential promoter TFBS or destabilizing element in
the 3′ UTR; (3) is in a highly conserved region; or (4) is
a tagging SNP (tagSNP) (on the basis of data from the
15 sequenced subjects).
We then genotyped 47 SNPs in whites, Han Chinese,
and African Americans, to calculate allele frequencies
(table 1). We determined the race-speciﬁc SNPs, whose
MAF is 13% in any of the ethnic study populations, and
identiﬁed 42 SNPs for whites, 33 for Asians, and 41 for
African Americans. We constructed haplotype structure
by use of the PHASE program and then used the PHASE
outcome to calculate the pairwise standardized disequi-
librium coefﬁcient (D′) with Haploxt, to estimate the
linkage magnitude between two SNPs, and depicted the
graphic overviews of LD by use of the GOLD program
(GOLD Web site). We identiﬁed haplotype blocks and
calculated haplotype frequencies in each block by use of
the HaploBlockFinder program (HaploBlockFinderWeb
site). Selection of the htSNPs in each ethnic group was
based on the condition that (1) the minimal combination
of htSNPs in each haplotype block represents 95% of
the haplotypes; (2) there is potential functionality in the
3′ UTR or promoter; or (3) the SNP is unlinked to any
block—for example, E2-C4T (the FokI RFLP).
Epidemiological Analysis
Genotype distribution was tested for Hardy-Wein-
berg equilibrium. Anthropometric measurements, BMI
(weight in kg/height in m2), bone mineral density (BMD)
(g/cm2; determined by dual energy x-ray absorptiometry
[Lunar DPX-L densitometer]) at the femoral neck and
lumbar spine (L2–L4), and other variables were mea-
sured as described elsewhere (Burger et al. 1994; Schuit
et al. 2004). BMD measurements were available for
5,027 subjects (82% of the cohort with genotypes). Sex-
speciﬁc T scores were calculated from the femoral neck
BMD by use of the NHANES reference population
(Looker et al. 1998) of white males and females aged
20–29 years. For assessment of the incidence of fracture,
follow-up ended before January 1, 2002 (mean follow-
up period years). We deﬁned “clinical frac-7.4 3.3
ture” to include all fractures conﬁrmed by general prac-
titioners or at hospitals, as described elsewhere (Fang et
al. 2003; Schuit et al. 2004), and we excluded head,
foot, hand, pathological, postprocedural, skull, and face
fractures. The presence of vertebral fracture was ana-
lyzed as described elsewhere (McCloskey et al. 1993;
Van der Klift et al. 2002).
We applied the Pearson x2 test to estimate differences
in fracture frequency by genotype. We calculated the
relative risk (RR) and 95% CI by logistic regression
models and calculated hazard ratio (HR) for incidence
of clinical, wrist, and hip fractures by Cox regression
model. Both the logistic and the Cox regression models
Figure 2 Conservation of the human and mouse genomic VDR gene sequence. The Y-axis is the homology rate between human and mouse; the X-axis is the physical distance on the
human VDR gene. All exons are indicated in purple, the 3′ UTR in light green, and the conserved noncoding region in red. The small black bars on the top of each frame indicate the
polymorphisms we observed by resequencing, and the gray arrow on top indicates the transcription direction of VDR.
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Figure 4 LDmaps ofVDR in different ethnic groups. The legend
is available in its entirety in the online edition of The American Journal
of Human Genetics.
Figure 3 LD structure of VDR in whites. a, Blocks with pairwise are numbered 1–5. The analyzed SNPs (table 1) include 39′D 1 0.8
VDR SNPs, 5 SNPs in the COL2A1 and VDR intergenic region (“IGR VDR & COL2A1”), and 3 SNPs in the VDR and HDAC7A intergenic
region (“IGR HDAC7A & VDR”). SNP IDs correspond to those in ﬁgure 1 and tables 1 and 5. The red boxes on the X- and Y-axes indicate
the high-LD blocks used to deﬁne haplotype alleles. The physical organization of VDR is represented with vertical lines on the Y-axis (see also
ﬁg. 1). b, Aligned LD analyses from different sources and estimated consensus LD structure of VDR. The total number of SNPs analyzed in
each study is indicated in parentheses. Thick lines indicate haplotype blocks, with the number of analyzed SNPs below the line and the name
of the block above the line.
were adjusted for potential confounders, such as age,
sex, height, weight, BMD, and bone loss. The popula-
tion-attributable risk (PAR) was calculated for genetic
and other markers for clinical fracture risk. All statistical
analyses were done using SPSS (version 11.0). The PAR
was calculated as ,P # (HR 1) / [P # (HR 1) 1]e e
where Pe is the proportion of the study population that
is exposed to the risk factor for fracture and where the
HR is for the risk factor.
Functional Experiments
Details on the electrophoretic gel mobility shift assay
(EMSA) and the transactivation assays for promoter
polymorphisms as well as the mRNA levels and stability
measurements for the 3′-UTR polymorphisms are pro-
vided in online-only appendix A. The oligonucleotides
used for EMSA are provided in table 2.
Results
Genomic Structure of VDR and Homology Analysis
The physical organization of the human VDR gene
region on chromosome 12q12-14 (kbp 46950–47350)
(ﬁg. 1a) and the VDR gene structure (ﬁg. 1b) is based
on PAC clones (PAC228P16 and PAC1057I20), data
from two published articles (Miyamoto et al. 1997;
Crofts et al. 1998), the Celera database, and our rese-
quencing efforts. VDR encompasses at least 105 kb;
the large 5′ region of noncoding exons 1f–1c is 60 kb,
with exon 1f located 35 kb upstream of exon 1e,
whereas exon 1e is 2 kb upstream of exon 1a. The
nearest genes are COL2A1, at a distance of 20 kb up-
stream (with a small gene-like structure, MGC5576,
close to COL2A1), and HDAC7A, at a distance of 10
kb downstream.
The overall percentage of identity between the entire
human and mouse VDR genomic sequences is 28.8%
(ﬁg. 2). Although coding exons were found in a highly
conserved region (86.5%–92.6% identity), except for
exon 5 (61.2% identity), we also observed regions of
high homology in intronic areas—in total, 14 kb of such
regions between exons 1f and 1e, 5 kb of regions be-
tween exons 1b and 1c, and a small 500-bp region be-
tween exons 2 and 3. Interestingly, there is a lack of
homology of human exons 1b, 1e, and 1f with themouse
gene, whereas exons 1a, 1d, and 1c are well conserved.
Overall, much of the lack of homology can be explained
by the presence of Alu repeats in the human VDR gene.
We detected 62 Alu-like sequences, mostly located in
introns and between exons 1f and 1e, although one is
located in the 3′ UTR (data not shown).
Resequencing of the VDR Gene
We found 62 polymorphisms (ﬁg. 1c and table 3),
including 57 SNPs and 5 VNTR polymorphisms, of
which 18 polymorphisms (including 15 SNPs) were not
present in the Celera database (chromosome 12, position
47033000–47139000 in the National Center for Bio-
technology Information [NCBI] Human Genome [build
35.1, April 2005 freeze]), the NCBI dbSNP (build 123),
the Human Gene Mutation Database (HGMD), the
HGBASE database, and/or other publications. Of 62
polymorphisms, 9 are located in highly conserved non-
coding regions (identity rate 170%) in the 3′ UTR and
the promoter region. The average frequency of variation
across 22 kb was 1/355 bp, with a range from 1/247 bp
(13/3.2 kb) in the 3′ UTR, to 1/315 (13/4.1 kb) in exons
2–9 and surrounding introns, to 1/408 (36/14.7 kb)
across the promoter region. Fifty SNPs with an MAF
5% in the 15 subjects were identiﬁed as “informative
SNPs.”
Three informative polymorphisms were located in the
so-called destabilizing elements (described elsewhere
[Durrin et al. 1999]) in the 3′ UTR of VDR (ﬁg. 1c).
Four informative SNPs were observed in coding exons
2–9: a previously identiﬁed CrT substitution (E2-C4T,
a FokI RFLP), E2-C59T and E8-C2T, which are syn-
onymous substitutions, and a previously identiﬁed syn-
onymous SNP (E9-T32C, detected as a TaqI RFLP).
In the promoter-region exons 1a–1f, we found 36 se-
quence variations, including 5 VNTRs and 31 SNPs.
One SNP in exon 1b (1b-C25A) would change the pre-
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Table 4
Characteristics of the Study Population
CHARACTERISTIC
VALUE FOR
TOTAL
COHORT
VALUE FOR COMBINED PROMOTER AND 3′-UTR
VDR GENOTYPEa
P0 1 2 or 3
No. (%) of individuals 6,148 1,586 (25.8) 3,560 (57.9) 1,002 (16.3) …
No. (%) of females 3,649 (59.4) 932 (58.8) 2,102 (59.0) 612 (61.1) .49
Age (years)b 69.5  9.1 69.1  9.1 69.5  9.1 70.0  9.4 .03
Height (cm)c 166.8  9.5 167.0  9.5 166.7  9.4 166.6  9.8 .16
Weight (kg)d 73.1  12.0 73.3  12.2 73.1  12.0 72.9  11.7 .55
Femural neck (FN) BMD (g/cm2)e .867  .142 .872  .143 .864  .142 .868  .145 .40
Lumbar spine BMD (g/cm2)e 1.090  .198 1.098  .197 1.089  .198 1.082  .199 .25
FN BMD change (103 g/cm2/year)f 2.1  9.4 1.6  8.6 1.9  9.5 3.2  10.0 .02
a The deﬁnition of the combined genotypes “0,” “1,” and “2 or 3” are given in table 6.
b Age was adjusted for sex.
c Height was adjusted for age and sex.
d Weight was adjusted for age, sex, and height.
e BMD (subset ) was adjusted for age, sex, height, and weight.np 5,027
f BMD change in 7.4 years follow-up (subset ) was adjusted for age, sex, and clinical fracture.np 2,391
dicted amino acid sequence by replacing a threoninewith
a lysine (1b-Thr8Lys). TRANSFAC analysis of the 5′
upstream regions of promoter exons 1a–1f indicated that
14 polymorphisms change the core recognition sequence
of potential transcription factors (see table 3).
LD and Haplotype Analyses
In whites, we identiﬁed ﬁve blocks with high LD (num-
bered 1–5 in ﬁg. 3a), which ranged in size from 2 to 17
kb. SNPs in such a block are in strong LD with the other
SNPs inside the block but show very little LD with SNPs
outside the block. Four blocks (blocks 1–4) were found
in the promoter region, whereas the largest block (block
5) encompasses 17 kb and includes exons 4–9 and the
3′ UTR. Blocks 2 and 3, encompassing the 1b–1e pro-
moter region, could not be considered as one LD block
in our analyses, even when is taken as the′D 1 0.50
cutoff to deﬁne a block. There are also clear areas of
very low (or absent) LD—that is, between exons 1e and
1f (blocks 1 and 2), between exons 2 and 3 (blocks 4
and 5), and at the end of VDR (3′ of block 5). The E2-
C4T SNP (the FokI RFLP) has no LD with any of the
other SNPs and cannot be assigned to any of the blocks.
The most distal 3′ haplotype block (block 5) shows no
LD with SNPs after VDR, and the most proximal 5′
(block 1) shows only weak LD with more 5′ SNPs near
and within COL2A1. At least seven blocks could be
identiﬁed when we compared different sources of VDR
LD block structures (ﬁg. 3b). It is difﬁcult to deﬁne the
exact boundaries of these low-LD areas because not all
studies analyzed a high density of SNPs across VDR.
Interestingly, we observed Line-1 repetitive elements to
be localized between the boundaries of the LD blocks
of VDR (ﬁg. 3b).
The LD map of Han Chinese is similar to that of
whites (ﬁgs. 1d and 4a), but with only four haplotype
blocks and with areas of low LD colocalizing with those
in whites. For Asians, we observed a large haplotype
block in the promoter region (from 1e-T3743C to 1b-
T391C), which corresponds to the combined blocks 2
and 3 in whites. This larger promoter block was also
observed in whites when we used SNPs with an MAF
5% (data not shown). The LD map of African Amer-
icans is more fragmented and is substantially different
from those of whites and Asians (ﬁgs. 1d and 4b). There
are eight small haplotype blocks and seven unlinked
SNPs. Again, the E2-C4T SNP (the FokI RFLP) was
found to be independent of any other haplotype block.
Some areas of low LD are colocalizing in all three ethnic
groups, indicated in ﬁg. 1d as A (separating exon 1f from
the upstream region to COL2A1), C (separating exon
1c from exons 1e–1b), D (separating exon 2 from exons
3–9/the 3′ UTR), and E (separating exon 4 to the 3′-
UTR from the area downstream of VDR), whereas B
(separating exon 1f from exons 1e–1b) is shared between
whites and African Americans but is absent in Han Chi-
nese. In African Americans, two additional areas of low
LD (B1 and B2) can be distinguished.
We reconstructed haplotype alleles and analyzed di-
versity and frequencies across ethnic groups (ﬁg. 1d; only
haplotypes with MAF 13% are shown). The number of
haplotype alleles in each of the LD blocks increases from
Han Chinese to whites and is largest in African Amer-
icans. Only for LD blocks relatively “conserved” across
ethnic groups is comparison possible, and this shows
substantial differences in haplotype allele frequencies.
For example, in block 1 (around exon 1f), the most
common allele in whites has a frequency of 44.6%, but
this same allele has a frequency of 4.7% in Han Chinese
and 10.3% in African Americans. Similarly, the most
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Figure 5 HR for clinical fracture, by VDR genotypes based on haplotype alleles in ﬁve haplotype blocks (1–5) and the FokI RFLP. The
HR point estimates and the surrounding 95% CIs are represented with colored squares and lines. The HR for one copy of the test allele versus
no copy is in blue; the HR for two copies of the allele versus no copy is in red. The logarithmic HR is plotted for the common haplotype alleles
(frequency 13%) in all haplotype blocks (see ﬁg. 1d for whites) and the FokI RFLP.
common allele in block 4 (around exon 1c) has fre-
quency 40.2% in whites, 32.3% in Han Chinese, and
13.8% in African Americans.
Although, for whites, 15 tagSNPs (14 htSNPs and E2-
C4T) are required to cover the common genetic diversity
across VDR, the required number is only 10 for Han
Chinese but increases to 28 for African Americans.
When only the tagSNPs were used to genotype a pop-
ulation (6,148 subjects from the Rotterdam Study), the
LD pattern obtained was similar to that obtained using
the 34 original SNPs with an MAF 15% in the smaller
sample of 234 blood-bank donors, which indicates that
the tagSNPs effectively predict the other SNPs within the
blocks.
We observed that the haplotypes constructed from the
well-known BsmI, ApaI, and TaqI RFLPs, as described
elsewhere by our group (Uitterlinden et al. 1996), could
correctly predict all the common haplotypes at the 3′
UTR in whites, deﬁned using the nine SNPs with an
MAF 15% (ﬁg. 1d). For Han Chinese, such correspon-
dence is lower because of the U-D796T polymorphism,
which has changed phase, whereas, for African Amer-
icans, the haplotype structure of this area is much
different.
Study of Association with Osteoporosis
Baseline characteristics of 6,148 white elderly of the
Rotterdam Study are presented in table 4. The 15 tag-
SNPs were in Hardy-Weinberg equilibrium. Haplotype
alleles in blocks 2, 3, and 5 had consistent—albeit not
always signiﬁcant—effects on clinical fractures (ﬁg. 5),
with similar effects in men and women and for vertebral,
hip, and wrist fractures (data not shown).
Subjects homozygous for the block 2–hap1 allele, ho-
mozygous for the block 3–hap3 allele, or carrying the
block 5–hap1 allele had an increased risk for clinical
fracture of 15% ( ), 74% ( ), and 23%Pp .06 Pp .002
( ), respectively (tables5 and 6). We then inves-Pp .004
tigated the combined effect of promoter and 3′-UTR risk
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Figure 6 EMSA of 1a-A1012G for GATA protein. The legend
is available in its entirety in the online edition of The American Journal
of Human Genetics.
Table 5
Incidence of Fractures in 6,148 Men and Women from the Rotterdam Study,
by VDR Genotype Deﬁned by Haplotype Allele Status in Blocks 2, 3, and 5
INDIVIDUAL LD BLOCK
AND MEASURED VALUE
GENOTYPE GROUPSa
PNonhomozygous Homozygous
Block 2–hap1:
No. of cases/total subjects (%) 695/4,844 (14.3) 211/1,304 (16.2) .06
Crude HR (95% CI) 1 1.15 (.97–1.35) .06
Block 3–hap3:
No. of cases/total subjects (%) 876/6,019 (14.6) 30/129 (23.3) .006
Crude HR (95% CI) 1 1.74 (1.22–2.50) .002
Noncarrier Carrier
Block 5–hap1:
No. of cases/total subjects (%) 256/1,988 (12.9) 650/4,160 (15.6) .004
Crude HR (95% CI) 1 1.23 (1.07–1.42) .004
NOTE.—Of 6,148 subjects overall, the total number of cases was 906 (14.7%).
The values in bold italics represent signiﬁcant associations.
a “Nonhomozygous” includes the genotype groups without the risk allele and the
heterozygotes. “Homozygous” is the genotype group homozygous for the risk allele.
“Noncarrier” is the genotype group without the risk allele, and “Carrier” includes
the genotype groups heterozygous and homozygous for the risk allele.
genotypes on fracture risk and found that subjects car-
rying two or three VDR risk genotypes had a 48% in-
creased risk for clinical fracture ( ). AlthoughPp .0002
age was borderline signiﬁcantly different by combined
VDR genotype, all associations with fracture were in-
dependent of age, sex, height, weight, and bone loss
(data not shown). By our observations, BMD did not
inﬂuence the association of individual or combined
blocks with fracture risk.
The PAR of the VDR genetic markers (table 7) was
1% (frequency of subjects homozygous for the block 3–
hap3 allelep 2%) and was 2% for the promoter region
(frequency of subjects homozygous for the block 2–hap1
allele p 21%) but increased to 12% for the 3′ region,
including the 3′ UTR (frequency of the block 5–hap1
allele carriers p 68%). This was higher than the 1%
PAR of the best validated genetic marker for osteopo-
rosis so far (COL1A1 Sp1 [Grant et al. 1996; Uitterlin-
den et al. 1998a]; in our study population, the frequency
of subjects homozygous for the Sp1 T allele was 3%)
and was similar to the PARs for smoking and use of a
walking aid.
Functionality Studies of Promoter Polymorphisms
Choosing from among 12 polymorphisms located at
potential TFBSs in the VDR promoter region, we per-
formed EMSA for four common (MAF 120%) SNPs (1e-
C2090T, 1e-G1739A, 1a-G1521C, and 1a-A1012G)
in the promoter region of exons 1e and 1a, using Caco2
or HEK293 nuclear extracts (ﬁg. 6). We identiﬁed a pu-
tative GATA-binding site for the A allele of the 1a-
A1012G SNP in the exon 1a promoter region (AGA-
TAT in reverse orientation) and demonstrated that the
G allele has markedly decreased binding to GATA com-
pared with that of the A allele.
Reporter constructs containing the 2-kb 1a-promoter
sequence with the two SNPs 1a-G1521C and 1a-
A1012G in block 2 (ﬁg. 7) showed that, in HEK293
cells, the normalized luciferase activity of the haplotype
allele was decreased by 53% and 50%, compared with
that of the hap 2/3 and hap 4/5 alleles, respectively
( and ). This indicates that the G7 7Pp 5 # 10 8 # 10
allele of the htSNP 1a-A1012G has a transcription rate
twofold lower than that of the A allele. The same results
were observed in COS-7 cells (data not shown).
Surrounding sequence analyses showed that the 1e-
C2090T and 1e-G1739A SNPs are located at po-
tential Cdx-2–binding sites (ﬁg. 8a). EMSA conﬁrmed
that the G allele of 1e-G1739A and the T allele of 1e-
C2090T have a relatively decreased binding to Cdx-
2, compared with their allelic counterparts (ﬁg. 8b). The
risk allele of the GATA and Cdx-2 promoter SNPs are
contained in block 2–hap1, which is the risk allele for
fracture.
Functionality Studies of 3′-UTR Polymorphisms
We found that, 24 h after transfection of reporter con-
structs containing the complete 3.2-kb 3′ UTR of hap1
or hap2, the neomycin-normalized VDR mRNA level
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Table 6
Incidence of Fractures in 6,148 Men and Women from the Rotterdam Study, by Combined VDR Genotype
MEASURED VALUE
AND FRACTURE TYPE TOTAL
NO. OF RISK GENOTYPES IN BLOCKS 2, 3, AND 5
TREND
P0a 1b 2 or 3c
No. of cases/total subjects (%):
Clinical fracture 906/6,148 (14.7) 207/1,586 (13.1) 516/3,560 (14.5) 183/1,002 (18.3) .001
Vertebral fractured 335/3,055 (11.0) 78/814 (9.6) 186/1,748 (10.6) 71/493 (14.4) .01
Hip fracture 261/6,148 (4.2) 61/1,586 (3.8) 144/3,560 (4.0) 56/1,002 (5.6) .05
Wrist fracture 257/6,148 (4.2) 58/1,586 (3.7) 145/3,560 (4.1) 54/1,002 (5.4) .04
Crude HR (95% CI):
Clinical fracture … 1 1.14 (.97–1.33) 1.48 (1.21–1.80) .0002
Vertebral fracture … 1 1.12 (.85–1.48) 1.59 (1.13–2.24) .01
Hip fracture … 1 1.06 (.79–1.43) 1.49 (1.04–2.14) .04
Wrist fracture … 1 1.13 (.83–1.53) 1.53 (1.06–2.21) .03
NOTE.—The values in bold italics represent signiﬁcant associations.
a “0” indicates the nonhomozygous genotype groups for blocks 2 and 3 (where “nonhomozygous” includes the genotype
groups without the risk allele and the heterozygotes) and the noncarrier genotype groups (i.e., the groups without the risk
allele) for block 5.
b “1” indicates either the homozygous genotype group (i.e., the group homozygous for the risk allele) for block 2 or 3 or
the carrier genotype group (i.e., the group with the risk allele) for block 5.
c “2 or 3” indicates two or three of the risk genotype groups—the homozygous genotype groups for blocks 2 and 3 and the
carrier genotype group for block 5.
d Vertebral fracture was diagnosed by x-ray.
of the hap1 transcript was 15% lower than that of the
hap2 transcript when results of all tested cell lines were
combined ( ; ), and similar patterns6Pp 2 # 10 np 53
were observed in individual cell lines (ﬁg. 9a and 9b).
We then investigated the stability of VDR mRNAs tran-
scribed from hap1 and hap2 and observed that the decay
rate of VDR mRNA for hap1 was 30% faster than that
for hap2 in the MG63 cell line 24 h after inhibiting
transcription ( ; ) (ﬁg. 9c).Pp .02 np 9
Discussion
A major limitation so far of association studies using
VDR polymorphisms in relation to complex-disease end
points has been the small number of analyzed poly-
morphisms and, thus, the lack of knowledge about the
inﬂuence of and relation between other polymorphisms
in the gene. In addition, the lack of statistical power of
most studies to detect the expected subtle effects as well
as the misconceptions about how such small biological
effects could be translated into risk of disease have led
to a number of controversies in the ﬁeld. In the current
study, we identiﬁed 62 polymorphisms in potentially
functional areas ofVDR, characterized the LD structure,
and identiﬁed htSNPs. We here combined several studies
and databases (Nejentsev et al. 2004; Hinds et al. 2005;
Applied Biosystems SNPbrowser Software Web site;
HapMap Data Web site; Perlegen Genome BrowserWeb
site) to conclude that there are seven haplotype blocks
across the VDR gene in whites. We used 15 tagSNPs to
represent the common haplotypes for ﬁve of these blocks
in potentially functional areas of VDR.
In this study, we also constructed an LD map and
identiﬁed htSNPs of VDR for three major ethnic pop-
ulations. There are several further approaches to iden-
tify the (set of) responsible functional SNPs in the LD
areas where we identiﬁed risk haplotype alleles. Since
African Americans have, in general, smaller LD blocks,
replication of the associations in African Americans
could focus on a smaller region with concomitantly
fewer SNPs to test functionally. Subsequently, the func-
tionality test we describe here (see ﬁgs. 7 and 9) can be
repeated, but with constructs of promoter and 3′-UTR
variants that differ at only one position.
A large association study with the htSNPs in a pop-
ulation-based cohort (6,148 elderly subjects) identiﬁed
haplotype alleles in three LD blocks that confer risk for
fracture, and we present evidence of intragenic additive
effects. These relationships were found in both men and
women and for different types of fractures (including
vertebral, hip, and wrist fractures) and were indepen-
dent of age, height, weight, BMD, and BMD change.
In our study population (which had a 15% prevalence
of fracture among 6,148 subjects), we have 80% sta-
tistical power to detect a 25% increased fracture risk
for a polymorphism and/or haplotype with a frequency
110%. We analyzed haplotypes instead of individual
SNPs, which limited the number of tests. For blocks 2
and 5, we did not adjust the signiﬁcant P value by the
conservative Bonferroni correction for multiple com-
parisons because, in our previous studies (Uitterlinden
et al. 2001; Fang et al. 2003), we observed two fracture-
risk alleles in these blocks in a subset of our current
study, and we conﬁrmed the association in this study—
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Table 7
PAR of Independent Risk Factors for Clinical Fracture in 6,148 Men and Women
from the Rotterdam Study
Risk Factor
Frequency
at Baseline
(%) HR (95% CI)a PAR in % (95% CI)a
Age 175 years 32 2.3 (2.1–2.6) 29 (25–34)
T score !2.5 16 2.7 (2.3–3.1) 21 (17–25)
Current smoking 23 1.3 (1.1–1.5) 6 (2–10)
Use of walking aid 12 1.3 (1.1–1.6) 3 (1–4)
Genetic markers:
COL1A1 Sp1 T-allele homozygote 3 1.4 (1.0–1.9) 1 (0–3)
VDR risk genotype:
Block 2–hap1 21 1.1 (.9–1.3) 2 (0–5)
Block 3–hap3 2 1.6 (1.2–2.4) 1 (0–3)
Block 5–hap1 68 1.2 (1.1–1.4) 12 (4–21)
Carrier of 2 or 3 VDR risk genotypes 16 1.3 (1.1–1.5) 4 (2–6)
a All HRs and PARs were adjusted for age and sex.
but this time for the haplotype alleles encompassing
the previously observed risk alleles. However, we used
(.05/11) on the basis of a Bonferroni correc-Pp .005
tion for analyses in the other three blocks and the FokI
RFLP; only the association between block 3–hap3 and
fracture risk remains borderline signiﬁcant ( ).Pp .002
Thus, we cannot reject the possibility that some of the
associations we observed are false positives, even in this
very large population.
According to our association analysis, the genetic ef-
fect of the VDR polymorphisms on fracture risk is mod-
est (15%–48%), which corresponds to the modest dif-
ference (15%) in the VDR mRNA level by genotype in
our functionality analysis. In an earlier study (Mann et
al. 2001), the “Ss” (or GT) genotype of COL1A1 Sp1
was found to have a 21% increased COL1A1:COL1A2
protein ratio, as measured in osteoblasts, compared
with that of the “SS” (or GG) genotype. Another func-
tional study of a 3′-UTR SNP (1073C/T in the oxi-
dized LDL receptor gene [OLR1]) that is associated
with increased risk for Alzheimer disease demonstrated
that C-allele carriers had a 41% decreased OLR1
mRNA level compared with that of TT homozygotes
(Lambert et al. 2003). These examples indicate that ge-
netic effects of polymorphisms on gene expression and
clinical phenotypes are modest.
Elsewhere, we reported that haplotype 1 of the 3′-end
variants, deﬁned by only BsmI-ApaI-TaqI RFLPs, was
associated with increased fracture risk in 1,004 post-
menopausal women (Uitterlinden et al. 2001), which is
a subgroup of the current study population. We here
conﬁrm this association between BsmI-ApaI-TaqI hap-
lotype 1 and fracture risk in the complete study pop-
ulation ( ; data not shown). Yet, in our morePp .03
detailed haplotype analysis based on more SNPs, we
deﬁned a subtype of the BsmI-ApaI-TaqI haplotype 1—
that is, of block 5–hap1u (40.2%) (ﬁg. 1d)—that shows
a stronger and more signiﬁcant association with fracture
risk. These subtle differences in the exact deﬁnition of
the risk allele could contribute to heterogeneity in as-
sociation results observed in different studies. Although
we focused here on the more common haplotype alleles
in the population, we cannot exclude the idea that (sev-
eral) less-frequent risk alleles may contribute to the
VDR genotype–dependent fracture risk. Further studies
will be necessary to assess their contribution. We show
that effects are modest (∼20%–70% increased risk), as
can be expected for common variants in relation to com-
plex disease. The VDR risk haplotype alleles therefore
have a modest inﬂuence on individual risk of fracture
but make a substantial contribution at the population
level (PAR p 4%–12%) in comparison with other ge-
netic markers we previously identiﬁed in this popula-
tion, such as COL1A1 Sp1 (Uitterlinden et al. 1998b)
and ESR1 PvuII and XbaI polymorphisms (van Meurs
et al. 2003). The most prominent genetic effect on frac-
ture risk, according to the PAR analyses, is the block
5–hap1 risk allele. Many previous conﬂicting associa-
tion studies ofVDR and BMD aswell as fracture usually
analyzed (very) small study populations and used the
BsmI, ApaI, or TaqI polymorphisms in this block but
mostly analyzed them separately. We therefore suppose
that the controversy can partly be explained by a lack
of statistical power as a result of small sample size and
failure to use haplotypes. In addition, population strat-
iﬁcation, such as mixed ethnic groups with different
allele frequencies; population-speciﬁc differences in
some environmental factors, such as (dietary) calcium
intake, (dietary) vitamin D intake, and sunlight expo-
sure; and other characteristics of the study population
pertinent to bone metabolism and fracture risk could
result in heterogeneity of association observed across
different study populations. On the basis of a meta-
analysis of published data on the relationship between
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Figure 7 Relative luciferase activity in HEK293 cells of VDR exon 1a promoter sequences, including two SNPs. a, The three constructs
containing the 2-kb 1a promoter sequence with SNPs 1a-G1521C and 1a-A1012G. b, b-galactosidase (beta-Gal)–normalized luciferase
activity for the three constructs. The block 2–hap1 allele is set at 100% to be the reference group; P values were calculated by independent t
test.
Figure 8 Two SNPs in the 1e promoter region of the human
VDR gene, located at a Cdx-2 binding site. The legend is available in
its entirety in the online edition of The American Journal of Human
Genetics.
the VDR BsmI RFLP and fracture risk, we have some
evidence that this could be an important factor (Y. Fang,
F. Rivadeneira, J. Ioannidis, and A. Uitterlinden, un-
published data). We have data on serum vitamin D and
on dietary calcium intake in a subset of our study pop-
ulation ( and 4,747, respectively), but we donp 1,312
not have reliable dietary vitamin D intake data. We note
that our study population has a very high dietary cal-
cium intake (1,120 mg/d). For the VDR-fracture rela-
tionship, we repeated the analyses but stratiﬁed them
by the median, tertiles, and quartiles of vitamin D level
or dietary calcium intake. However, the association did
not differ between these strata, and no interaction was
observed (data not shown).
By analyzing functionality of the risk alleles in vitro,
we demonstrate that the molecular mechanisms under-
lying these associations are likely to involve a lower
expression of VDR mRNA. Some of the promoter poly-
morphisms result in altered transcription-factor binding
for Cdx-2 and GATA. The previously reported Cdx-2
site at 1e-G1739A (Yamamoto et al. 1999; Fang et
al. 2001) and the GATA site at 1a-A1012G (Halsall
et al. 2005) are encompassed in the block 2–hap1 risk
allele. Our functionality experiment and previous ones
(Arai et al. 2001) show that these two weak-binding
alleles together result in decreased transcription activity
of this VDR promoter. Further research is needed to
establish, in more detail, in which cells and/or tissues
this promoter part is inﬂuencing VDR expression. Al-
though GATA is expressed in many tissues, Cdx-2 is
expressed predominantly in the intestines. Thus, the
hap1 allele might cause relatively lowerVDR expression
in target cells for vitamin D, including the intestines.
The 3′ UTR of genes is known to be involved in reg-
ulation of gene expression, especially through regula-
tion of mRNA stability. The BsmI, ApaI, and TaqI SNPs
are anonymous, and block 5 does not include poly-
morphisms beyond the 3′ UTR of VDR. Therefore,
SNPs in the 3′ UTR are the most likely candidates for
the truly functional sequence variations that may ex-
plain the associations we observed. We identiﬁed dif-
ferences in VDR mRNA expression level and stability
between the hap1 and hap2 alleles, which differ at only
ﬁve positions across the 3.2-kb 3′ UTR. The fracture-
risk allele hap1 causes 15% lower levels of mRNA ex-
pression than does hap2, in all tested cell lines. This is
in line with the 30% faster decay of or lower stability
of VDR mRNA we observed in MG63, an osteoblast
cell line. This observation also corresponds to other
studies performed in vivo and in vitro (Morrison et al.
1992, 1994; Carling et al. 1997; Ogunkolade et al.
Figure 9 VDR mRNA expression level and stability analysis by 3′-UTR haplotypes in different cell lines. a, VDR 3′-UTR with sequence
variations that distinguish hap1 (corresponding to block 5–hap1) from hap2 (corresponding to block 5–hap2). The SNP variation number (in
parentheses) refers to those given in table 3. b, Neomycin-normalized VDR mRNA expression levels (mean  SD) for VDR 3′-UTR hap1
versus hap2. The level of hap2 is set at 100% to be the reference group; P values were calculated by independent t test; n p number of
experiments for each cell line. c, Decay rate of VDR mRNA by hap1 versus hap2, determined in the MG63 cell line. Time point 0 h is deﬁned
as 100% mRNA level for both haplotypes; P values for each time point were calculated by independent t test.
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2002). This is likely to also result in lower numbers of
VDR protein being present in target cells for vitamin
D, giving such target cells a decreased response to vi-
tamin D.
VDR as a transcription factor inﬂuences the expres-
sion of downstream genes, such asTRPV5, TRPV6, and
Calbindin, which are involved in calcium absorption
and could therefore impact BMD and thus fracture risk.
However, we found that the association between VDR
genotype and fracture risk was independent of BMD,
which suggests that other mechanisms (such as bone
microarchitecture, bone quality, and bone strength) de-
termine fracture risk. Alternatively, we can hypothesize
that the bone tissue of the subjects carrying a risk allele
may have a somewhat lower sensitivity to vitamin D,
since the expression of VDR is lower. Therefore, the
osteoblast activity could be lower, and the bone for-
mation rate (in the bone-remodeling balance) could be
decreased. The age-related expansion of the outer di-
ameter of long bone is associated with a marked incre-
ment of bone strength. We have observed recently that
the fracture-risk haplotype alleles were also associated
with decreased bone size (Y. Fang, J. van Meurs, F.
Rivadeneira, N. van Schoor, J. van Leeuwen, P. Lips,
H. Pols, and A. Uitterlinden, unpublished data) in the
same population. This genotype-related bone geometry
difference reﬂects that the bone gain resulting in outer
bone diameter expansion is smaller than the bone loss
resulting in inner bone diameter expansion. This bone
geometry difference leads to a decrease in bone strength
for the risk-allele carriers, possibly increasing the frac-
ture risk.
We demonstrate that polymorphisms within the pro-
moter area and the 3′-UTR area of a gene have effects
that can inﬂuence VDR gene function in certain cells
and/or subjects. Thus, the 5′-promoter and 3′-UTRpoly-
morphisms together can determine howmuch of a given
VDR mRNA level will be expressed in a given target
cell. The combined risk genotypes in the promoter re-
gion and 3′ UTR represent a moderate genetic effect of
the entire VDR gene on fracture risk. The vitamin D
endocrine system has been implicated in several other
complex diseases, including osteoarthritis, diabetes, and
cancer. Whether our ﬁndings have relevance for these
other diseases needs to be tested in separate association
studies using the LD and haplotype information we pro-
vide here.
In conclusion, we systematically scanned sequence
variations across VDR, identiﬁed LD structure and
htSNPs for different ethnic populations, and demon-
strated that polymorphisms in the 5′ promoter region
and the 3′ UTR of VDR contribute to fracture risk in
a large population. Functionality experiments in the 5′
promoter region and the 3′ UTR support and provide
a possible molecular explanation for the association
with fracture risk that we observed.
Acknowledgments
We thank Drs. John Eisman and Linda Crofts for helpful
sharing of unpublished sequence information; Dr. Mark Haus-
sler for kindly providing VDR cDNA; and Marco Eijken for
initial help with the RT-PCR in the 3′-UTR experiments. We
thank all participants of the Rotterdam Study and the general
practitioners, the pharmacists, and the many ﬁeld workers at
the research center in Ommoord, Rotterdam, TheNetherlands.
This project was funded by the Dutch Research Organisation
(NWO grants 903-46-178, 925-01-010, 014-90-001, and 911-
03-012) and the European Commission (grant QLK6-CT-
2002-02629 [“GENOMOS”]).
Web Resources
Accession numbers and URLs for data presented herein are
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(for reference sequences [accession numbers BV210413–
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browser/index.html
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TFSEARCH: Searching Transcription Factor Binding Sites,
http://www.cbrc.jp/research/db/TFSEARCH.html
Vista Tools, http://www-gsd.lbl.gov/VISTA/index.shtml
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